MiMedx Q2 sales fall less than expected; set to acquire Sanara MedTech
MDXG•Outlook reiterated for 2026
- MiMedx reiterated 2026 net sales guidance of $260 million to $290 million.
- The company expects 2026 adjusted EBITDA to approach breakeven.
- MiMedx sees long-term annual net sales growth in the low double-digits.
Sales drivers and key figures
Result drivers
- Surgical growth — Surgical product sales rose 15% yr/yr, led by AMNIOFIX and AMNIOEFFECT, according to CEO Joseph Capper.
- Wound business decline — Wound sales fell 61% yr/yr due to Medicare reimbursement changes effective Jan. 1.
- Cost reduction actions — The company took steps to reduce expenses early in Q2, contributing to lower SG&A costs.
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Beat | $64.36 mln | $63.46 mln (5 Analysts) |
| Q2 Net Loss | $14.84 mln | ||
| Q2 Adjusted EBITDA | Miss | -$8.12 mln | $2.06 mln (5 Analysts) |
| Q2 Gross Profit |
